First-line lenvatinib plus pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.

被引：0

作者：

Lee, Chung-Han

Gurney, Howard

Atduev, Vagif

Suarez, Cristina

Duran, Miguel A. Climent

Pook, David William

Tomczak, Piotr

Barthelemy, Philippe

Lee, Jae-Lyun

Nalbandian, Taron

Stus, Viktor

Ferguson, Thomas

Wiechno, Pawel

Gokmen, Erhan

Lacombe, Louis

Gedye, Craig

Burgents, Joseph

Sharma, Manish

Peng, Xiang

Albiges, Laurence

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Macquarie Univ, Sydney, NSW, Australia

[3] Fed Med Biol Agcy, Volga Dist Med Ctr, Nizhnii Novgorod, Russia

[4] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[5] Inst Valenciano Oncol, Valencia, Spain

[6] Monash Hlth, Melbourne, Vic, Australia

[7] Poznan Univ Med Sci, Poznan, Poland

[8] Inst Cancerol Strasbourg Europe, Strasbourg, France

[9] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[10] Reg Canc Ctr, Kharkiv, Ukraine

[11] Dnipro State Med Univ, Dnipro, Ukraine

[12] Fiona Stanley Hosp, Perth, WA, Australia

[13] Inst Marii Sklodowskiej Curie, Oncol Ctr, Warsaw, Poland

[14] Ege Univ, Fac Med, Izmir, Turkiye

[15] CHU Quebec, Ctr Rech, Quebec City, PQ, Canada

[16] Univ Newcastle, Callaghan, NSW, Australia

[17] Merck & Co Inc, Rahway, NJ 07065 USA

[18] Gustave Roussy, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4518

引用

页数：1

共 50 条

[41] Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial
Fitzgerald, Kelly N.
Lee, Chung-Han
Voss, Martin H.
Carlo, Maria I.
Knezevic, Andrea
Peralta, Laura
Chen, Yingbei
Lefkowitz, Robert A.
Shah, Neil J.
Owens, Colette N.
Mchugh, Deaglan J.
Aggen, David H.
Laccetti, Andrew L.
Kotecha, Ritesh R.
Feldman, Darren R.
Motzer, Robert J.
EUROPEAN UROLOGY, 2024, 86 (02) : 90 - 94
[42] Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.
Flippot, Ronan
McGregor, Bradley Alexander
Flaifel, Abdallah
Gray, Kathryn P.
Signoretti, Sabina
Steinharter, John A.
Van Allen, Eliezer Mendel
Walsh, Meghara K.
Gundy, Katy
Wei, Xiao X.
Harshman, Lauren Christine
Vaishampayan, Ulka N.
Choueiri, Toni K.
McKay, Rana R.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[43] First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
Buti, Sebastiano
Bersanelli, Melissa
Massari, Francesco
De Giorgi, Ugo
Caffo, Orazio
Aurilio, Gaetano
Basso, Umberto
Carteni, Giacomo
Caserta, Claudia
Galli, Luca
Boccardo, Francesco
Procopio, Giuseppe
Facchini, Gaetano
Fornarini, Giuseppe
Berruti, Alfredo
Fea, Elena
Naglieri, Emanuele
Petrelli, Fausto
Iacovelli, Roberto
Porta, Camillo
Mosca, Alessandra
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (11): : 1037 - 1046
[44] Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
Rini, Brian I.
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem
Waddell, Tom
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor O.
Azevedo, Sergio Jobim
Borchiellini, Delphine
McDermott, Raymond S.
Bedke, Jens
Tamada, Satoshi
Wu, Sterling
Burgents, Joseph
Molife, L. Rhoda
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA4501 - LBA4501
[45] Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).
Graham, Jeffrey
Wells, Connor
Dudani, Shaan
Gan, Chun Loo
Donskov, Frede
Lee, Jae-Lyun
Kollmannsberger, Christian K.
Pal, Sumanta K.
Beuselinck, Benoit
Hansen, Aaron Richard
North, Scott A.
Bjarnason, Georg A.
Agarwal, Neeraj
Kanesvaran, Ravindran
Wood, Lori
Hotte, Sebastien J.
McKay, Rana R.
Choueiri, Toni K.
Heng, Daniel Yick Chin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[46] Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426
Rini, Brian I.
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem
Waddell, Tom
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor O.
Azevedo, Sergio Jobim
Borchiellini, Delphine
McDermott, Raymond S.
Bedke, Jens
Tamada, Satoshi
Wu, Sterling
Burgents, Joseph
Molife, L. Rhoda
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[47] Randomized, open-label, 3-arm phase III study comparing MK-1308A+lenvatinib and pembrolizumab (pembro) plus belzutifan plus lenvatinib versus pembro plus lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)
Rini, B. I.
Plimack, E. R.
Powles, T. B.
Voss, M. H.
Gurney, H. P.
Silverman, R.
Perini, R.
Rodriguez-Lopez, K.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2021, 32 : S722 - S723
[48] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.
Lee, Chung-Han
Shah, Amishi Yogesh
Hsieh, James J.
Rao, Arpit
Pinto, Alvaro
Bilen, Mehmet Asim
Cohn, Allen Lee
DiSimone, Christopher
Shaffer, David R.
Sarrio, Regina Girones
Ribe, Sara Gunnestad
Wu, Jane
Schmidt, Emmett V.
Kubiak, Peter
Okpara, Chinyere
Smith, Alan D.
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[49] Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Choueiri, Toni K.
Eto, Masatoshi
Motzer, Robert
De Giorgi, Ugo
Buchler, Tomas
Basappa, Naveen S.
Mendez-Vidal, Maria Jose
Tjulandin, Sergei
Park, Se Hoon
Melichar, Bohuslav
Hutson, Thomas
Alemany, Carlos
McGregor, Bradley
Powles, Thomas
Gruenwald, Viktor
Alekseev, Boris
Rha, Sun Young
Kopyltsov, Evgeny
Kapoor, Anil
Gordoa, Teresa Alonso
Goh, Jeffrey C.
Staehler, Michael
Merchan, Jaime R.
Xie, Ran
Perini, Rodolfo F.
Mody, Kalgi
McKenzie, Jodi
Porta, Camillo
LANCET ONCOLOGY, 2023, 24 (03): : 228 - 238
[50] An exploratory prospective clinical study on efficacy and safety of anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma
Dong, P.
Wei, W.
Jiang, L.
Zhang, Z.
Guo, S.
Han, H.
Cai, X.
Zhou, F.
EUROPEAN UROLOGY, 2023, 83 : S753 - S753

← 1 2 3 4 5 →